Luccini Elisa, Musante Veronica, Neri Elisa, Raiteri Maurizio, Pittaluga Anna
Pharmacology and Toxicology Section, Department of Experimental Medicine, University of Genoa, Viale Cembrano 4, Genoa, Italy.
J Neurosci Res. 2007 Dec;85(16):3657-65. doi: 10.1002/jnr.21446.
Presynaptic NMDA autoreceptors regulating glutamate release have rarely been investigated. High-micromolar N-methyl-D-aspartate (NMDA) was reported to elicit glutamate release from hippocampal synaptosomes in a Ca(2+)-independent manner by reversal of excitatory amino acid transporters. The aim of this work was to characterize excitatory amino acid release evoked by low-micromolar NMDA from glutamatergic axon terminals. Purified rat hippocampal synaptosomes were prelabelled with [(3)H]D-aspartate ([(3)H]D-ASP) and exposed in superfusion to varying concentrations of NMDA in the presence of 1 microM glycine. The release of [(3)H]D-ASP and also that of endogenous glutamate provoked by 10 microM NMDA were external Ca(2+) dependent and sensitive to the NMDA channel blocker MK-801 but insensitive to the glutamate transporter inhibitor DL-TBOA, which, on the contrary, prevented the Ca(2+)-independent release evoked by 100 microM NMDA. The NMDA (10 microM) response was blocked by 1 nM Zn(2+) and 1 microM ifenprodil, compatible with the involvement of a NR1/NR2A/NR2B assembly, although the presence of two separate receptor populations, i.e., NR1/NR2A and NR1/NR2B, cannot be excluded. This response was strongly antagonized by submicromolar (0.01-1 microM) concentrations of kynurenic acid and was mimicked by quinolinic acid (1-100 microM) plus 1 microM glycine. Finally, the HIV-1 protein gp120 potently mimicked the NMDA co-agonists glycine and D-serine, being significantly effective at 30 pM. In conclusion, glutamatergic nerve terminals possess NMDA autoreceptors mediating different types of release when activated by different agonist concentrations: low-micromolar glutamate would potentiate glutamate exocytosis, whereas higher glutamate concentrations would also provoke carrier-mediated release.
调节谷氨酸释放的突触前N-甲基-D-天冬氨酸(NMDA)自身受体很少被研究。据报道,高微摩尔浓度的N-甲基-D-天冬氨酸(NMDA)可通过兴奋性氨基酸转运体的逆转以不依赖Ca(2+)的方式引发海马突触体释放谷氨酸。这项工作的目的是表征低微摩尔浓度的NMDA从谷氨酸能轴突终末引发的兴奋性氨基酸释放。纯化的大鼠海马突触体用[(3)H]D-天冬氨酸([(3)H]D-ASP)预先标记,并在1 microM甘氨酸存在下在灌注中暴露于不同浓度的NMDA。[(3)H]D-ASP的释放以及由10 microM NMDA引发的内源性谷氨酸的释放均依赖于细胞外Ca(2+),并且对NMDA通道阻滞剂MK-801敏感,但对谷氨酸转运体抑制剂DL-TBOA不敏感,相反,DL-TBOA可阻止100 microM NMDA引发的不依赖Ca(2+)的释放。NMDA(10 microM)反应被1 nM Zn(2+)和1 microM艾芬地尔阻断,这与NR1/NR2A/NR2B组装体的参与一致,尽管不能排除存在两种不同的受体群体,即NR1/NR2A和NR1/NR2B。该反应被亚微摩尔浓度(0.01 - 1 microM)的犬尿氨酸强烈拮抗,并被喹啉酸(1 - 100 microM)加1 microM甘氨酸模拟。最后,HIV-1蛋白gp120有效地模拟了NMDA共激动剂甘氨酸和D-丝氨酸,在30 pM时具有显著效果。总之,谷氨酸能神经终末具有NMDA自身受体,当被不同浓度的激动剂激活时介导不同类型的释放:低微摩尔浓度的谷氨酸会增强谷氨酸胞吐作用,而较高浓度的谷氨酸也会引发载体介导的释放。